1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
GC Biopharma Corp.

GC Biopharma Corp.

006280.KS
GC Biopharma Corp.KR flagKorea Exchange
123,600.00
KRW
+3,000.00
- -
1.41TMarket Cap
GC Biopharma Corp.
006280.KS
(Korea Exchange)

Recent

price

123,600.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
79,945.18
71,720.05
74,876.91
77,831.35
84,351.69
90,617.22
103,697.33
112,835.92
116,973.22
119,014.21
131,781.28
134,746.56
149,945.12
142,497.41
147,213.07
174,679.84
179,006.7
Revenue per Share
10,580.52
5,171.08
4,947.96
6,140
7,260
8,213
5,451
4,665
3,017
-319
7,101
10,796
5,735
-2,333
-2,303
-410
-1,217.51
Basic EPS, GAAP
5,734.64
-15.81
-2,093.43
-5,341.28
-1,207.02
-7,817.52
-8,691.97
202.3
-4,436.29
-9,412.08
-5,731.83
213.82
2,143.54
-11,516.55
-8,399.69
-510.17
2,797.82
Free Cash Flow per Basic Share
1,135.92
1,623.11
1,427.12
1,129.76
1,274.66
1,299.7
1,774.59
1,343.12
1,342.99
1,085.54
1,114.36
1,621.97
2,101.57
2,174.7
1,711.66
1,651.93
2.36
Dividend per Share
35,461.37
37,251.59
40,186.14
44,193.84
49,457.55
56,549.52
60,221.62
64,472.93
65,185.52
63,183.52
71,467.56
81,118.68
84,281.61
81,594.49
76,570.47
74,999.36
75,204.06
Book Value per Share
53,862.12
55,995.7
59,664.02
69,621.55
74,896.04
81,075.25
85,301.58
89,433.18
89,851.22
94,804.94
101,609.4
107,104.22
109,969.92
105,296.16
102,848.13
92,720.85
85,698.24
Tangible Book Value per Share
10
11
11
11
12
12
12
11
11
11
11
11
11
11
11
11
11
Basic Weighted Avg Shares
791,015
767,912
811,774
888,168
975,327
1,047,812
1,197,904
1,287,916
1,334,878
1,357,117
1,504,115
1,537,826
1,711,313
1,626,644
1,679,892
1,991,279
2,043,032
Sales/Revenue/Turnover
18.41
11.47
9.16
8.87
9.94
8.75
6.55
7.01
3.76
3.07
3.34
4.79
4.75
2.12
1.91
3.47
3.57
Operating Margin (%)
19,235
13,035
15,660
18,425
23,521
28,426
31,073
36,724
40,130
46,666
48,791
55,904
65,096
75,899
81,034
87,655
88,154
Depreciation Expense
104,689
55,367
53,643
70,066
83,945
94,967
62,970
53,247
34,429
-3,638
81,049
123,212
65,453
-26,632
-26,280
-4,674
-13,896
Net Income, GAAP
22.28
33.07
23.93
20.87
25.6
25.76
18.06
21.4
31.71
- -
14.71
20.64
19.03
- -
- -
- -
58
Effective Tax Rate (%)
13.23
7.21
6.61
7.89
8.61
9.06
5.26
4.13
2.58
-0.27
5.39
8.01
3.82
-1.64
-1.56
-0.23
-0.68
Profit Margin (%)
329,106
317,418
237,523
351,967
328,511
435,726
498,080
666,482
589,948
560,357
542,640
542,738
439,699
170,232
432,359
224,585
258,406
Working Capital
42,014
9,271
8,129
20,590
38,025
74,000
149,545
306,989
263,320
342,817
264,552
371,312
376,547
191,426
435,917
358,597
355,422
LT Debt
542,234
630,281
685,233
839,409
920,627
997,704
1,059,011
1,108,713
1,126,207
1,184,077
1,269,306
1,499,757
1,566,642
1,539,863
1,481,016
1,394,273
1,308,971
Total Equity
20.02
9.03
7.76
7.43
7.21
6.01
5.18
5.16
2.37
- -
2.44
2.94
3.07
- -
- -
- -
- -
Return on Invested Capital (%)
27.23
12.75
10.88
12.64
12.72
12.34
7.09
5.14
3.53
- -
5.69
7.26
4.32
- -
- -
- -
15.91
Return on Capital (%)
34.61
14.77
12.86
14.91
15.6
15.5
9.33
7.44
4.65
-0.5
10.55
14.15
6.93
-2.81
-2.91
-0.54
-1.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
681,662
623,547
558,905
LT Borrowings
232,805
253,501
260,645
LT Finance Leases
108,450
105,096
94,776
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
1,474,554
1,814,660
1,630,941

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,494,708
1,370,388
1,297,835
Cash, Cash Equivalents & STI
68,517
50,804
42,727
Accounts Receivable, Net
541,325
402,689
371,080
Inventories
849,437
891,582
857,519
Total Current Liabilities
1,270,873
1,145,803
1,039,429
Payables & Accruals
- -
- -
- -
ST Debt
681,662
623,547
558,905
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.6%
2.25%
-5.86%
Free Cash Flow
-227.03%
8.08%
-93.93%
Net Income, GAAP
-274.23%
-43.82%
-82.22%
Sales/Revenue/Turnover
6.84%
6.08%
18.54%
Total Cash Common Dividend
4.84%
10.74%
-3.59%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
356,810
417,363
464,866
440,854
1,679,892
2025
383,779
500,260
609,486
497,755
1,991,279
2026
435,532
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2,218
-608
2,915
- -
-2,303
2025
2,602
3,328.53
1,397.07
- -
-410
2026
1,793.87
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,711.66
2025
- -
- -
- -
- -
1,651.93
2026
2.36
- -
- -
- -
- -
Similar Companies
Kiniksa Pharmaceuticals International, plc (KNSA)
Inyx, Inc. (IYXI)
Nova Cannabis Inc. (NOVC.TO)
Sanofi India Limited (SANOFI.NS)
Pharmaids Pharmaceuticals Limited (PHARMAID.BO)
Cybin Inc. (CYBN.NE)
Business
GC Biopharma Corp. (006280.KS) manufactures and markets biopharmaceutical products with a focus on plasma-derived therapeutics, recombinant proteins, vaccines, and immunology treatments in South Korea and internationally. The company offers an extensive portfolio of plasma derivatives including Albumin-GCC injection for hypoalbuminemia and shock, Antithrombin-III for hereditary deficiencies, Fibrinogen for hypofibrinogenemia, Gamma Globulin and I.V.-Globulin SN for immune deficiencies, Hepabig and I.V. Hepabig for hepatitis B prevention and recurrence, and Greenplast Q for tissue sealing; recombinant products such as GreenGene F and GreenGene for hemophilia A, Facnyne for hemophilia B, Green-VIII for factor VIII supply, and Hunterase for Hunter syndrome; vaccines like GCFLU Quadrivalent and GC FLU pre-filled syringes for influenza prevention, Varicella Vaccine, Sero-Tet for tetanus prophylaxis, and BARYCELA chickenpox vaccine; immunology therapies including Immuncell-LC for liver cancer, Histobulin for bronchial asthma, and IV-Globulin (Alyglo) for autoimmune conditions; over-the-counter drugs such as Acustop Cataplasma, Kenhancer plaster, Zenol Cool Type, and Shinbaro for pain relief and anti-inflammation. Founded in 1967 and headquartered in Yongin-si, Gyeonggi-do, South Korea, GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation, maintains manufacturing facilities in South Korea including Hwasun, Jeollanam-do, and conducts R&D in rare diseases, bleeding disorders, lysosomal storage diseases, oncology, and next-generation mRNA/LNP platforms while distributing to over 50 countries. Recent developments include securing CMO rights for Curevo Vaccine's shingles vaccine amezosvatein in October 2025 to expand its vaccine portfolio; acquiring three orphan hematology programs including subcutaneous Marzeptacog alfa (MarzAA) from Catalyst Biosciences in February 2023 for Phase 3-ready rare bleeding disorder treatments; advancing clinical trials for Hunterase ICV intracerebroventricular injection in Korea following Japan approval; pursuing U.S. approval and launch of intravenous immunoglobulin GC5107 (Alyglo) to enter the plasma market; and maintaining a research agreement with Novelty Nobility for antibody therapeutics targeting geographic atrophy.

Company News

APIChatGPT

  • headlinesoftoday.com

    GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea